FindTrial
Sign In

INCB 54828-801: An Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in Studies of Pemigatinib

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-503406-36-00
Acronym
INCB 54828-801
Enrollment
4
Registered
2023-06-09
Start date
2021-12-13
Completion date
2023-05-11
Last updated
2023-06-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Male and female participants at least 18 years of age who are actively receiving treatment with pemigatinib under a parent protocol and receiving clinical benefit and who do not have access to pemigatinib outside of a clinical trial

Brief summary

Frequency and nature of AEs and SAEs as assessed by CTCAE v5.0.

Interventions

DRUGPemazyre 13.5 mg tablets
DRUGPemazyre 4.5 mg tablets
DRUGPemazyre 9 mg tablets
DRUGPemigatinib

Sponsors

Incyte Corp., Incyte Corp.
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Frequency and nature of AEs and SAEs as assessed by CTCAE v5.0.—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026